膀癌的预后分析与缩相关的基因
Huang Xiaolong1,2, Deng Min1, Zhang Sizhou2
1, Department of Urology, the Second Affiliated Hospital, Third Military Medical University (Army Medical University), Xinqiao Road No.83, Chongqing, 400037, P. R. China.
Hereditas
|June 16, 2025
概括
六个与化相关的基因显示出作为膀癌 (BLCA) 存活的独立指标的前景. 使用这些基因的预后模型证明了BLCA患者的显著诊断疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 缩修饰与瘤进展和微环境变化有关.
- 了解缩在膀癌 (BLCA) 中的作用对于预后至关重要.
研究的目的:
- 调查缩在BLCA进展中的作用.
- 确定BLCA中与缩相关的基因的预后意义.
主要方法:
- 权重基因共同表达网络分析 (WGCNA) 和TCGA数据确定了缩基因模块.
- 拉索和考克斯回归分析开发了基于枢纽基因的预后模型.
- 蛋白与蛋白相互作用网络,GSEA和单细胞测序探索了基因功能;RT-qPCR验证了表达.
主要成果:
- WGCNA确定了1412个与缩相关的枢纽基因;选择了6个关键基因 (CUL1,PUM2,UBE2D3,HIF3A,COPS2,DDB1).
- PUM2,HIF3A在正常组织中表达高;DDB1在瘤组织中升调.
- 一个预后模型实现了卓越的诊断效率 (AUC>0.77) 并揭示了免疫反应和亡中的基因作用.
结论:
- 六个与缩相关的基因 (CUL1,PUM2,UBE2D3,HIF3A,COPS2,DDB1) 是BLCA潜在的独立生存指标.
- 开发的生存模型显示了膀癌的显著诊断效果.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


